GH Fragment 176-191
Also known as: hGH 176-191, AOD9604-related fragment, HGH Frag
GH Fragment 176-191 (also called hGH 176-191 or AOD9604-related fragment) is a GH C-terminal fragment. This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism.
For research use only.
Key Facts
- CAS
- 66004-57-7
- Molecular Weight (MW)
- ≈1729 g/mol
- Half-life
- Short (minutes–hours; animal PK)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Adipose lipolytic pathways
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 4
- Listed offers
- 4
- Price per mg
- $8.69–$12.00/mg
Research summary
C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's GH Fragment 176-191 profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
GH Fragment 176-191 dosage: no established human dose
GH fragment 176-191 has no established human dosage. No human trial of it is published or registered. Its evidence comes from mouse studies of AOD9604, a closely related fragment of the end of human growth hormone, which reduced weight gain and body fat in obese mice given it by injection into the abdominal cavity for 14 days or by mouth for 30 days.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: GH fragment 176-191 is the end segment of human growth hormone, studied for its fat-burning (lipolytic) effect without growth hormone's other actions. The published work is in mice and used the related fragments AOD9604 and AOD-9401. No human study has tested the fragment itself, so no dose, route or interval is established.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| AOD9604 (a related growth hormone fragment) in obese mice, 14 days (2001)Preclinical · Animal study of a related peptideStudied an analog, not GH Fragment 176-191 itself | Obese mice and beta-3 adrenergic receptor knock-out mice | Not stated in the indexed abstract | Intraperitoneal | — | 14 days | Lower body weight and body fat in obese mice; no weight effect in the knock-out mice | The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. |
| Oral growth hormone fragment (AOD-9401) in obese mice, 30 days (2000)Preclinical · Animal study of a related peptideStudied an analog, not GH Fragment 176-191 itself | Obese (ob/ob) mice; isolated rodent and human fat tissue | Not stated in the indexed abstract | Oral | — | 30 days | Less weight gain from day 16, with no change in food intake | Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000. |
Where sources disagree
- GH fragment 176-191 and AOD9604 are often treated as the same compound but differ by one added amino acid. Mouse results with AOD9604 are listed as related-peptide evidence, not as evidence for this fragment.
- The AOD-9604 profile records that it has no published human dose either, so it cannot supply one for this fragment.
Reconstitution
Common research vial sizes: 5 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Timing Notes
- Studied for lipolytic signaling; not approved.
Sequence & molecular data
| Molecular formula | C78H123N23O23S2 |
|---|---|
| Molecular weight | ≈1729 g/mol |
| CAS number | 66004-57-7 |
| Half-life | Short (minutes–hours; animal PK) |
| Appearance | White lyophilized powder (acetate) |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism. The rationale for isolating it is that the growth-promoting and insulin-antagonising actions of growth hormone are mediated through receptor-driven JAK2/STAT5 signalling and hepatic IGF-1 production, whereas the lipolytic effect was thought to be separable. In rodent adipocyte studies the fragment increased lipolysis and reduced lipogenesis without raising IGF-1. Human evidence for meaningful fat loss is weak, and the fragment does not reproduce the anabolic effects of intact growth hormone.
Origin
Synthetic fragment of human growth hormone.
Targets
Studies
Research statistics
2 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
GH Fragment 176-191 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
GH Fragment 176-191 side effects
GH Fragment 176-191 has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Injection reactions
- Uncertain efficacy
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
GH Fragment 176-191: frequently asked questions
What is GH Fragment 176-191?
C-terminal fragment of human GH studied for lipolysis. Closely related to AOD-9604. Not FDA-approved. WADA S2 (GH fragments).
How does GH Fragment 176-191 work?
This is the C-terminal fragment of human growth hormone spanning residues 176 to 191, the region associated with the hormone's effects on fat metabolism. The rationale for isolating it is that the growth-promoting and insulin-antagonising actions of growth hormone are mediated through receptor-driven JAK2/STAT5 signalling and hepatic IGF-1 production, whereas the lipolytic effect was thought to be separable.
Is GH Fragment 176-191 FDA approved?
No. GH Fragment 176-191 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of GH Fragment 176-191?
Reported half-life for GH Fragment 176-191 is Short (minutes–hours; animal PK). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is GH Fragment 176-191 banned in sport?
GH Fragment 176-191 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to GH Fragment 176-191?
Compounds most often compared with GH Fragment 176-191 include AOD-9604, Human Growth Hormone (Somatropin), 5-Amino-1MQ and Adipotide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026External reference
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices — Analyst, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This GH Fragment 176-191 profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track GH Fragment 176-191 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →